INZY News and Press, Inozyme Pharma Inc. From 03/22/23

- Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO - - Matthew Winton, Ph.D., appointed COO - - Upcoming clinical and regulatory milestones remain on track with previous guidance - - Current cash, cash equivalents and short-term i...

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company...

Summary Shares are down 58% over the past year. Enzyme replacement therapy is an attractive area of drug development with less risk than more exotic modalities like gene therapy. Enterprise value is just $15M as contrasted to aggregate blockbuster opportunity across two rare disease...

3 Tips for Finding Short Term Penny Stocks to Buy When it comes to trading penny stocks, many investors focus on the short-term gains that can be achieved through careful selection of stocks that have the potential to increase in value in a short period of time. However, finding the right p...

Inozyme Pharma ( NASDAQ: INZY ) shares surged ~36% on Thursday after the rare-disease-focused biotech announced topline data from its Phase 1/2 studies for lead candidate INZ-701 and raised its outlook for cash runway. The global trials were designed to evaluate INZ-701 in adults ...

- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and significant increase in PPi observed in all dose cohorts with sustained increase observed in high...

- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE) – BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...

- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 – - Significant clinical and scientific milestones across ENPP1 Deficiency and ABCC6 Deficiency programs achieved in 2022 - ...

- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate - - Company estimates addressable patient population with ENPP1 Deficiency at 37,000 worldwide; 2,800 in North America, 4,1...

BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s...